23.03.2018 • NewsCristalElaine BurridgeTronox

EU Objects to Tronox-Cristal Merger

EU Objects to Tronox-Cristal Merger
EU Objects to Tronox-Cristal Merger

The European Commission has issued a statement of objections to Tronox regarding its proposed $2.4 billion acquisition of Cristal’s titanium dioxide (TiO2) business. Tronox is required to respond to the objections by early April.

“The statement of objections further details and clarifies the commission’s position, and receipt of it establishes a defined framework to move forward,” said Tronox CEO Jeffry Quinn. We continue in constructive dialogue, and I am confident we can determine an appropriate and proportionate resolution to any valid concerns of the Commission.”

The mining and inorganic chemicals company added that the statement of objections does not prejudge the outcome of the Commission’s investigation nor the need to offer any particular remedy.

Tronox is already suing the US Federal Trade Commission (FTC) on the deal, alleging the agency is using delaying tactics to block the acquisition, which was originally announced in February 2017.

On Mar. 1, the companies extended their purchase agreement from May 21 to Jun. 30, with automatic three-month extensions perpetuating until Mar. 21 2019, to allow more time to secure the outstanding regulatory approvals.

The deal has already been cleared by the authorities in Australia, China, New Zealand, Turkey, South Korea and Colombia.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.